Paging Dr. McClellan: FDA Calls On Brookings For PDUFA Research
This article was originally published in The Pink Sheet Daily
Executive Summary
Brookings’ Engelberg Center for Health Care Reform invited to help FDA research REMS and risk-benefit standardization, patient-reported outcomes, and other issues that were mandated in PDUFA V.
You may also be interested in...
Biomarker Development Meeting May Help Expand Accelerated Approval
FDA could develop more guidance on how sponsors can qualify potential surrogate endpoints.
Biomarker Development Meeting May Help Expand Accelerated Approval
FDA could develop more guidance on how sponsors can qualify potential surrogate endpoints.
“Complete Response” Letters Might Include Benefit-Risk Framework Discussion
FDA official says idea could be helpful; meanwhile, sponsors and others remain concerned about the framework’s undefined decision-making methods.